Brahms' procalcitonin test:
This article was originally published in Clinica
Brahms has received US 510(k) clearance of its procalcitonin (PCT) Kryptor test to assess patients' risk for severe sepsis and septic shock. The test, which provides results in less than an hour, will be used in critically ill patients in the intensive care unit to determine whether an infection is bacterial or viral. Bacterial infections can be treated quickly with antibiotics, while these drugs can be avoided in patients with viral infection (inappropriate use of antibiotics contributes to the increase in antibiotic-resistant bacteria). PCT levels are undetectable in healthy people, but bacterial infections cause levels to rise. This is not seen with viral infections. The first automated PCT test to reach the US market, bioMerieux's VIDAS B.R.A.H.M.S PCT test (licensed from Hennigsdorf, Germany-based Brahms in 2005), was approved in the US last October.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.